Sequana Medical
- Home ›
- BE ›
- Healthcare
Sequana Medical NV, a commercial stage medical device company, focuses on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites, and other fluid imbalance disorders. The last earnings update was 88 days ago. More info.
Add to Portfolio Compare Print
SEQUA Share Price and Events
7 Day Returns
1 Year Returns
SEQUA Shareholder Return
| 7 Day | 30 Day | 90 Day | 1 Year | 3 Year | 5 Year | |
|---|---|---|---|---|---|---|
| Sequana Medical (SEQUA) | 1.3% | 0.9% | -1.8% | - | - | - |
| Europe Medical Equipment | 0.4% | -0.2% | 6.3% | 4.6% | 59.7% | 91.9% |
| BE Market | 2.7% | 3.6% | -0.9% | -5.8% | -10.7% | 8.8% |
1 Year Return vs Industry and Market
- No trading data on SEQUA.
- No trading data on SEQUA.
Value
Value is all about what a company is worth versus what price it is
available for. If you went into a grocery store and all the bananas were on sale
at half price, they could be considered
undervalued.
In this section, we usually try to help investors determine whether Sequana Medical is trading at an attractive price based on the cash flow it is expected to produce in the future. But as Sequana Medical has not provided consistent financial data, and the stock also has no analyst forecast or coverage, its intrinsic value cannot be reliably calculated by extrapolating past data or using analyst consensus cash flow predictions.
This is quite a rare situation as 89% of companies covered by Simply Wall St do have a valuation analysis. You can see them here.
Show me the analysis anyway
- It is not possible to calculate the future cash flow value for Sequana Medical. This is due to cash flow or dividend data being unavailable. The share price is €6.48.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for
it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing
when they are out of season, or how much your home is worth.The amount the stock market is willing to pay for Sequana Medical's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are
Sequana Medical's earnings available for a low price, and how does
this compare to other companies in the same industry?
| Data Point | Source | Value |
|---|---|---|
| Earnings Per Share * | Company Filings (2018-12-31) in EUR | €-1.40 |
| ENXTBR:SEQUA Share Price ** | ENXTBR (2019-07-19) in EUR | €6.48 |
| Europe Medical Equipment Industry PE Ratio | Median Figure of 59 Publicly-Listed Medical Equipment Companies | 31.98x |
| Belgium Market PE Ratio | Median Figure of 87 Publicly-Listed Companies | 14.99x |
* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.
** Primary Listing of Sequana Medical.
| Calculation | Outcome | |
|---|---|---|
| PE Ratio | = ENXTBR:SEQUA Share Price ÷ EPS (both in EUR) = 6.48 ÷ -1.40 |
-4.63x |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Sequana Medical is loss making, we can't compare its value to the Europe Medical Equipment industry average.
- Sequana Medical is loss making, we can't compare the value of its earnings to the Belgium market.
Price based on expected Growth
Does
Sequana Medical's expected growth come at a high price?
| Data Point | Source | Value |
|---|---|---|
| PE Ratio | See PE Ratio Section | -4.63x |
| Net Income Annual Growth Rate | See Future Growth Section. Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts |
18.5%per year |
| Europe Medical Equipment Industry PEG Ratio | Median Figure of 41 Publicly-Listed Medical Equipment Companies | 2.42x |
| Belgium Market PEG Ratio | Median Figure of 40 Publicly-Listed Companies | 1.83x |
*Line of best fit is calculated by linear regression .
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to calculate PEG ratio for Sequana Medical, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on
Sequana Medical's
assets?
| Data Point | Source | Value |
|---|---|---|
| Book Value per Share | Company Filings (2018-12-31) in EUR | €-5.87 |
| ENXTBR:SEQUA Share Price * | ENXTBR (2019-07-19) in EUR | €6.48 |
| Europe Medical Equipment Industry PB Ratio | Median Figure of 139 Publicly-Listed Medical Equipment Companies | 3.28x |
| Belgium Market PB Ratio | Median Figure of 119 Publicly-Listed Companies | 1.55x |
| Calculation | Outcome | |
|---|---|---|
| PB Ratio | = ENXTBR:SEQUA Share Price ÷ Book Value per Share (both in EUR) = 6.48 ÷ -5.87 |
-1.1x |
* Primary Listing of Sequana Medical.
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Sequana Medical has negative assets, we can't compare the value of its assets to the Europe Medical Equipment industry average.
Value checks
We assess Sequana Medical's value by looking at:- Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
- Is the PE ratio less than the market average, and/ or less than the Medical Equipment industry average (and greater than 0)? (2 checks)
- Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
- Is the PB ratio less than the Medical Equipment industry average (and greater than 0)? (1 check) Sequana Medical has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.
Full details on the Value part of the Simply Wall St company analysis model.
Future Performance
The future performance of a company is measured in the same way as past
performance, by looking at estimated
growth
and how much profit it is expected to make.Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Earnings growth vs Low Risk Savings
- Unable to compare Sequana Medical's earnings growth to the low risk savings rate as it is expected to be loss making during the next 1-3 years.
Growth vs Market Checks
- Unable to compare Sequana Medical's earnings growth to the Belgium market average as it is expected to be loss making during the next 1-3 years.
- Sequana Medical's revenue growth is expected to exceed the Belgium market average.
Annual Growth Rates Comparison
| Data Point | Source | Value (per year) |
|---|---|---|
| ENXTBR:SEQUA Future Earnings Growth Rate | Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts | 18.5% |
| ENXTBR:SEQUA Future Revenue Growth Rate | Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts | 51% |
| Europe Medical Equipment Industry Earnings Growth Rate | Market Cap Weighted Average | 18.1% |
| Europe Medical Equipment Industry Revenue Growth Rate | Market Cap Weighted Average | 7.1% |
| Belgium Market Earnings Growth Rate | Market Cap Weighted Average | 8% |
| Belgium Market Revenue Growth Rate | Market Cap Weighted Average | 3.8% |
*Line of best fit is calculated by linear regression .
Industry and Market average data is calculated daily.
Learn more about our growth rate calculations in Simply Wall St’s analysis model.
Analysts growth expectations
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (6 months ago) | See Below |
| Future Estimates | Average of up to 2 Analyst Estimates (S&P Global) | See Below |
| Date (Data in EUR Millions) | Revenue | Cash Flow | Net Income * | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | 35 | 1 | ||
| 2022-12-31 | 14 | -4 | -3 | 1 |
| 2021-12-31 | 6 | -13 | -12 | 2 |
| 2020-12-31 | 3 | -11 | -12 | 2 |
| 2019-12-31 | 2 | -16 | -13 | 1 |
| Date (Data in EUR Millions) | Revenue | Cash Flow | Net Income * |
|---|---|---|---|
| 2018-12-31 | 1 | -10 | -14 |
| 2018-09-30 | 1 | -8 | -10 |
| 2017-12-31 | 1 | -8 | -8 |
| 2016-12-31 | 1 | -13 | -14 |
*GAAP earnings excluding extraordinary items.
Past and Future Earnings per Share
| Data Point | Source | Value |
|---|---|---|
| Past Financials | Company Filings (6 months ago) | See Below |
| Future Estimates | Average of up to 2 Analyst Estimates (S&P Global) | See Below |
All data from Sequana Medical Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in EUR Millions) | EPS * | EPS High Estimate | EPS Low Estimate | Avg. No. Analysts |
|---|---|---|---|---|
| 2023-12-31 | ||||
| 2022-12-31 | -0.20 | -0.20 | -0.20 | 1.00 |
| 2021-12-31 | -0.94 | -0.40 | -1.47 | 2.00 |
| 2020-12-31 | -0.92 | -0.68 | -1.16 | 2.00 |
| 2019-12-31 | -1.00 | -1.00 | -1.00 | 1.00 |
| Date (Data in EUR Millions) | EPS * |
|---|---|
| 2018-12-31 | -1.40 |
| 2018-09-30 | -1.06 |
| 2017-12-31 | -0.88 |
| 2016-12-31 | -2.10 |
*GAAP earnings excluding extraordinary items.
Performance in 3 years
In the same way as past performance we look at the future estimated return
(profit) compared to the available
funds. We do this looking forward 3 years.
- Unable to establish if Sequana Medical will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
Future performance checks
We assess Sequana Medical's future performance by looking at:- Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
- Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Europe market? (1 check)
- Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Europe market? (1 check)
- Is the annual earnings growth rate expected to be above 20%? (1 check)
- Is the annual revenue growth rate expected to be above 20%? (1 check)
- Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Sequana Medical has a total score of 2/6, see the detailed checks below.
Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.
Full details on the Future part of the Simply Wall St company analysis model.
Past Performance
How has Sequana Medical performed over the past 5 years?
The past performance of a company can be measured by how much
growth
it has experienced and how much profit it makes relative to the funds and assets
it has available.
Past earnings growth
Past Earnings growth analysis
- Sequana Medical does not make a profit and there is insufficient past data to establish if their 5 year on year earnings growth rate was positive.
- Unable to compare Sequana Medical's 1-year earnings growth to the 5-year average as it is not currently profitable.
- Unable to compare Sequana Medical's 1-year growth to the Europe Medical Equipment industry average as it is not currently profitable.
Earnings and Revenue History
All data from Sequana Medical Company Filings, last reported 6 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.
| Date (Data in EUR Millions) | Revenue | Net Income * | G+A Expenses | R&D Expenses |
|---|---|---|---|---|
| 2018-12-31 | 1.03 | -13.98 | 9.16 | 1.81 |
| 2018-09-30 | 1.03 | -10.42 | 9.18 | 1.15 |
| 2017-12-31 | 1.30 | -8.23 | 7.51 | 1.00 |
| 2016-12-31 | 1.49 | -13.97 | 13.99 | 1.15 |
| 2015-12-31 | 1.68 | -11.56 | 11.95 | 0.99 |
*GAAP earnings excluding extraordinary items.
Performance last year
We want to ensure a company is making the most of what it has available. This is
done by comparing the return (profit) to a company's available
funds,
assets
and
capital.
- It is difficult to establish if Sequana Medical has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) due to its liabilities exceeding its assets.
- It is difficult to establish if Sequana Medical has efficiently used its assets last year compared to the Europe Medical Equipment industry average (Return on Assets) as it is loss-making.
- It is difficult to establish if Sequana Medical improved its use of capital last year versus 3 years ago (Return on Capital Employed) due to its liabilities exceeding its assets.
Past performance checks
We assess Sequana Medical's performance over the past 5 years by checking for:- Has earnings increased in past 5 years? (1 check)
- Has the earnings growth in the last year exceeded that of the Medical Equipment industry? (1 check)
- Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
- Is the Return on Equity (ROE) higher than 20%? (1 check)
- Is the Return on Assets (ROA) above industry average? (1 check)
- Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
Sequana Medical has a total score of 0/6, see the detailed checks below.
Note: We use GAAP Net Income excluding extraordinary items in all our calculations.
Full details on the Past part of the Simply Wall St company analysis model.
Health
How is Sequana Medical's financial health and their level of debt?
A company's financial position is much like your own financial position,
it includes everything you own
(assets)
and owe
(liabilities).The boxes below represent the relative size of what makes up Sequana Medical's finances.
The net worth of a company is the difference between its assets and liabilities.
- Sequana Medical's short term (1 year) commitments are greater than its holdings of cash and other short term assets.
- Sequana Medical's long term commitments exceed its cash and other short term assets.
Balance sheet
Assets
Liabilities and shares
- High level of physical assets or inventory.
- Sequana Medical has negative shareholder equity (liabilities exceed assets) therefore debt is not covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t
bad,
however if the debt is too high, or the company can’t afford to pay the interest
on its debts this may have impacts in the future.The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.
If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
All data from Sequana Medical Company Filings, last reported 6 months ago.
| Date (Data in EUR Millions) | Total Equity | Total Debt | Cash & Short Term Investments |
|---|---|---|---|
| 2018-12-31 | -18.76 | 14.65 | 1.32 |
| 2018-09-30 | -13.35 | 10.92 | 0.54 |
| 2017-12-31 | -4.61 | 4.58 | 1.68 |
| 2016-12-31 | -6.67 | 4.66 | 0.80 |
| 2015-12-31 | -0.28 | 0.00 | 1.43 |
- Sequana Medical has negative shareholder equity (liabilities exceed assets), this is a more serious situation compared with a high debt level.
- Irrelevant to check if Sequana Medical's debt level has increased considering it has negative shareholder equity.
CASH RUNWAY ANALYSIS
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
- Sequana Medical has less than a year of cash runway based on current free cash flow.
- Sequana Medical has less than a year of cash runway if free cash flow continues to reduce at historical rates of -11.3% each year.
Financial health checks
We assess Sequana Medical's financial health by checking for:- Are short term assets greater than short term liabilities? (1 check)
- Are short term assets greater than long term liabilities? (1 check)
- Has the debt to equity ratio increased in the past 5 years? (1 check)
- Is the debt to equity ratio over 40%? (1 check)
- Is the debt covered by operating cash flow? (1 check)
- Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check) Sequana Medical has a total score of 0/6, see the detailed checks below.
- Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
- Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
Full details on the Health part of the Simply Wall St company analysis model.
Dividends
What is Sequana Medical's current dividend yield, its reliability and sustainability?
Dividends are regular cash payments to you from the company, similar to a
bank paying you interest on a savings account.
Annual Dividend Income
If you bought
€2,000 of
Sequana Medical
shares you are expected to receive
€0
in your first year as a dividend.
Dividend Amount
- Unable to evaluate Sequana Medical's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
- Unable to evaluate Sequana Medical's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not
wildly increasing/decreasing each year. This graph shows you the historical rate
to count toward your assessment of the stock.We also check to see if the dividend has increased in the past 10 years.
| Data Point | Source | Value |
|---|---|---|
| Past Annualized Dividend Yield | S&P Global Market Data | See Below |
| Past Dividends per Share | Company Filings/ Annualized Dividend Payments | See Below |
| Future Dividends per Share Estimates | Average of up to 2 Analyst Estimates (S&P Global) | See Below |
| Europe Medical Equipment Industry Average Dividend Yield | Market Cap Weighted Average of 40 Stocks | 1.5% |
| Belgium Market Average Dividend Yield | Market Cap Weighted Average of 77 Stocks | 3.5% |
| Belgium Minimum Threshold Dividend Yield | 10th Percentile | 1.2% |
| Belgium Bottom 25% Dividend Yield | 25th Percentile | 2.3% |
| Belgium Top 25% Dividend Yield | 75th Percentile | 4.6% |
Industry and Market average data is calculated daily.
Note all dividend per share amounts are annualized and not quarterly or other period.
| Date (Data in €) | Dividend per Share (annual) | Avg. No. Analysts |
|---|---|---|
| 2023-12-31 | ||
| 2022-12-31 | ||
| 2021-12-31 | ||
| 2020-12-31 | ||
| 2019-12-31 |
Learn more about our ratios and growth rates in Simply Wall St’s analysis model >
- Unable to perform a dividend volatility check as Sequana Medical has not reported any payouts.
- Unable to verify if Sequana Medical's dividend has been increasing as the company has not reported any payouts.
Income/ dividend checks
We assess Sequana Medical's dividend by checking for:- Firstly is the company paying a notable dividend (greater than 1.2%) - if not then the rest of the checks are ignored.
- Is current dividend yield above the bottom 25% of dividend payers? (1 check)
- Is current dividend yield above the top 25% of dividend payers? (1 check)
- Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
- If they have paid a dividend for 10 years has it increased in this time? (1 check)
- How sustainable is the dividend, can Sequana Medical afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks) Sequana Medical has a total score of 0/6, see the detailed checks below.
Full details on the Dividends part of the Simply Wall St company analysis model.
Management
CEO
CEO Bio
Mr. Ian Crosbie is the Chief Executive Officer of Sequana Medical NV. Mr. Crosbie has been the Chief Executive Officer of Sequana Medical AG since December 22, 2016. He served as Chief Financial Officer of Sequana Medical AG from July 1, 2016 to December 22, 2016. He served as Chief Financial Officer at Global Consolidated Aesthetics Limited. Mr. Crosbie served as the Chief Financial Officer of GC Aesthetics PLC since January 2015 and served as its Principal Accounting Officer. He served as Senior Vice President of Corporate Development at Circassia Limited since 2013. Mr. Crosbie joined Circassia Limited on November 2013 and worked until December 2014. He has extensive senior-level strategic advisory experience in the life sciences industry. He served as Head of Healthcare Investment Banking at Jefferies Group LLC (formerly Jefferies Group, Inc.) since March 18, 2008. He served as a Managing Director in the healthcare investment banking group at Jefferies International Limited from March 2008 to April 2013. He served as Director of Healthcare Investment Banking at Deutsche Bank. He served as Managing Director at Ferghana Partners Group, a founder and Partner at Gargoyle Partners and a Director in the healthcare investment banking group at Deutsche Bank AG. He was founder of Gargoyle Partners in 2003 and joined FPG through the combination of the two firms in 2005. Together with Rawle Michelson, Mr. Crosbie was responsible for FPG’s activities in Europe across all product areas. He was Founder of Gargoyle Associates Ltd. and served as its Executive Officer. He was an Independent Corporate Consultant from May 2013 to October 2013. He is an experienced healthcare investment banker having worked for more than twelve years across all sectors of the industry, including pharmaceuticals, biotech, life sciences enabling tools, devices, diagnostics and services. He has a track record in M&A and equity & debt capital raising. Mr. Crosbie began his career with Bain & Co. as a Strategic Management Consultant both in London and California, before moving into investment banking with Baring Brothers in London. He then joined the healthcare team of Alex. Brown & Sons and was one of the original members of that team in Europe. Following the acquisition by Bankers Trust and Deutsche Bank. He served as co-head of Deutsche Bank’s European healthcare investment banking group, covering both financing and advisory products and all sectors of the industry. He served as an Equity Analyst of Deutsche Bank AG, Research Division. In 2003, Mr. Crosbie joined Rawle Michelson to found Gargoyle Partners and was a leading player in establishing the Rawle Michelson’s presence in the healthcare sector. He served as a Second Lieutenant in the 32ndArmoured Engineer Regiment of the British Army Mr. Crosbie received his MA (Oxon) in Engineering, Economics and Management from Oxford University.
CEO Compensation
- Insufficient data for Ian to compare compensation growth.
- Insufficient data for Ian to establish whether their remuneration is reasonable compared to companies of similar size in Belgium.
Management Team
Ian Crosbie
CEO & Executive Director
Kirsten Van Bockstaele
Chief Financial Officer
44
Lies Vanneste
Director of Investor Relations
0.3 yrs
Gijs Klarenbeek
Chief Medical Officer
42
Martijn Blom
Chief Commercial Officer
45
Board of Directors Tenure
Average tenure and age of the Sequana Medical board of directors in years:
- The average tenure for the Sequana Medical board of directors is less than 3 years, this suggests a new board.
Board of Directors
Pierre Chauvineau
Chairman
55
0.4 yrs
Ian Crosbie
CEO & Executive Director
0.4 yrs
Rudy DeKeyser
Non-Executive Director
57
Erik Amble
Non-Executive Director
67
Wim Ottevaere
Independent Non-Executive Director
63
0.4 yrs
Jason Hannon
Independent Non-Executive Director
47
0.2 yrs
Who owns this company?
Recent Insider Transactions
| Announced | Type | Name | Entity | Role | Start | End | Shares | Max Price (€) | Value (€) | |
|---|---|---|---|---|---|---|---|---|---|---|
Management checks
We assess Sequana Medical's management by checking for:- Is the CEO's compensation unreasonable compared to market cap? (1 check)
- Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
- Is the average tenure of the management team less than 2 years? (1 check)
- Is the average tenure of the board of directors team less than 3 years? (1 check) Sequana Medical has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.
Note: We use the top 6 management executives and board members in our calculations.
Note 2: Insider trading include any internal stakeholders and these transactions .
Full details on the Management part of the Simply Wall St company analysis model.
Company Info
Description
Sequana Medical NV, a commercial stage medical device company, focuses on the development of treatment solutions for the management of liver disease, heart failure, malignant ascites, and other fluid imbalance disorders. Its products include alfapump, a treatment solution for the long-term management of liver refractory ascites and malignant ascites; and alfapump DSR, a fully implanted system for direct sodium removal therapy in patients with volume overload due to heart failure. The company was founded in 2006 and is headquartered in Ghent, Belgium.
Details
| Name: | Sequana Medical NV |
| SEQUA | |
| Exchange: | ENXTBR |
| Founded: | 2006 |
| €102,689,817 | |
| 15,847,194 | |
| Website: | http://www.sequanamedical.com |
| Address: |
Sequana Medical NV AA Tower, Technologiepark 122, Ghent, East Flanders, 9052, Belgium |
Listings
| Exchange Symbol | Ticker Symbol | Security | Exchange | Country | Currency | Listed on | |
|---|---|---|---|---|---|---|---|
| ENXTBR | SEQUA | Ordinary Shares | Euronext Brussels | BE | EUR | 11. Feb 2019 | |
| BST | 2SE | Ordinary Shares | Boerse-Stuttgart | DE | EUR | 11. Feb 2019 |
Number of employees
Current staff
Industry
| Health Care Equipment | |
| Healthcare |
Company Analysis and Financial Data Status
| Area | Date (UTC time) |
|---|---|
| Company Analysis updated: | 2019/07/20 23:11 |
| End of day share price update: | 2019/07/19 00:00 |
| Last estimates confirmation: | 2019/06/05 |
| Last earnings filing: | 2019/04/23 |
| Last earnings reported: | 2018/12/31 |
| Last annual earnings reported: | 2018/12/31 |
All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
